Clinical trials: Psoriasis, open to volunteers
Psoriasis, Psoriatic Arthritis
Genetic Variation in TRAF3IP2 (rs13190932)
Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population.
- Trial name
- NCT07086924
- Testing
- Methotrexate
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- South Valley University
Inflammatory Joint Diseases
The Norwegian Antirheumatic Drug Register
NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs…
- Trial name
- NOR-DMARD (NCT01581294)
- Where
- 6 sites in Norway
- Volunteers
- 15,000 people
- Sponsor
- Diakonhjemmet Hospital
Psoriasis
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis.
- Trial name
- NCT05642182
- Testing
- SFA002
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- SFA Therapeutics
Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis…
- Trial name
- NCT07166315
- Testing
- observational study
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Adelphi Real World
Plaque Psoriasis, Vitamin D3
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis.
- Trial name
- NCT04036188
- Testing
- Triamcinolone, Vitamin D3
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wright State University
Psoriasis
Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales.
- Trial name
- NCT07128472
- Testing
- Humira
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- South Valley University
Psoriasis
Is Monitoring Enhanced Auto-fluorescence Beneficial for the Precise Removal of Tissue From Psoriatic Lesions With Ablative Lasers?
It is known that psoriatic lesions clear and remain cleared if you remove them from the skin. This can be done through surgery and ablative laser therapy.
- Trial name
- NCT07130019
- Testing
- Fluorescence guided thermal ablation of epidermal tissue, Thermal ablation of epidermal tissue
- Where
- Netherlands
- Volunteers
- 47 people
- Sponsor
- Nick van der Beek
Psoriatic Arthritis, Psoriasis (PsO)
Inflammation Digital Biomarkers Validation Study
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease.
- Trial name
- IDBV (NCT07594054)
- Volunteers
- 3,458 people
- Sponsor
- University of Oxford
Rheumatic Diseases, Inflammatory Arthritis
Personalized Outreach for Equitable Treatment in Rheumatology
The primary goal of this study is to determine whether providing patient honoraria and/or outreach services can improve the attendance rate of appointments at an inner city rheumatology clinic in Vancouver, British Columbia.
- Conditions
- Rheumatic Diseases, Inflammatory Arthritis, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
- Trial name
- POET-Rheum (NCT07022756)
- Testing
- Honoraria, Outreach
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
The primary objective is to demonstrate the superiority of BKZ (dual inhibition of IL-17A and IL-17F) on the ASAS40 response at 6 months compared to a reference treatment (ADA) in patients with active axial or predominantly axial…
- Trial name
- ThoracSPA (NCT07836283)
- Testing
- bimekizumab, adalimumab
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Psoriatic Arthritis
Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic Arthritis
This prospective single-center interventional study aims to investigate the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on disease activity, pain, quality of life, autonomic dysfunction symptoms, and…
- Trial name
- NCT07653009
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Marmara University
Plaque Psoriasis
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis.
- Trial name
- NCT07733089
- Testing
- ZP9830
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Zealand Pharma
Noncommunicable Disease, Psoriasis
Impact of Hand Rub Placement on Patient Trust and Disease Stigma
This study aims to investigate how the physical placement of hand sanitizer in consultation rooms affects patient trust and feelings of disease stigma.
- Trial name
- NCT07552792
- Testing
- Distant placement of hand rub, Conventional placement of hand rub
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Psoriasis Vulgaris
Psoriatic Immune Response to Tildrakizumab
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
- Trial name
- NCT05390515
- Testing
- Tildrakizumab Prefilled Syringe
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Plaque Psoriasis
Understanding Participation Habits Among Plaque Psoriasis Patients
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention.
- Trial name
- NCT06338358
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Psoriasis (PsO), Traditional Chinese Medicine (TCM)
Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators
Psoriasis Vulgaris is a chronic, inflammatory, and immune-activated skin disease. It is the most common type of psoriasis, accounting for approximately 85-90% of all psoriasis patients.
- Conditions
- Psoriasis (PsO), Traditional Chinese Medicine (TCM), Diagnosis
- Trial name
- NCT07351448
- Testing
- No intervention
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Psoriasis
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or…
- Trial name
- NCT05270733
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University Hospitals Cleveland Medical Center
Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07326813
- Testing
- D-2570 Tablet, BMS-986165 Tablet
- Where
- China
- Volunteers
- 477 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.
- Trial name
- NCT04347473
- Testing
- Ilumya Injectable Product
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey